Case number 1:22-cv-01395
Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc., et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jul 3, 2024 | 202 | NOTICE OF SERVICE of (i) the Rebuttal Expert Report of Dr. Richard L. McCreery, Ph.D. on behalf of Nanjing Noratech Pharmaceutical Co., Limited and Gerbera Therapeutics, Inc. (with Exs. A-C); (ii) the Responsive Expert Report of Dr. Clare Strachan, Ph.D. on behalf of Nanjing Noratech Pharmaceutical Co., Limited and Gerbera Therapeutics, Inc. (with Appendix I and Exs. A-C); and, (iii) the Rebuttal Expert Report of Jeremy Karl Cockroft, Ph.D. on behalf of Nanjing Noratech Pharmaceutical Co., Limited and Gerbera Therapeutics, Inc. (with Exs. A-C) filed by Novartis Pharmaceuticals Corporation, Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 07/03/2024) (2) |
| Jul 3, 2024 | 203 | NOTICE OF SERVICE of Responsive Expert Report of Dr. Jonathan W. Steed Regarding MSNs Non-Infringement of United States Patent No. 11,096,918 [HIGHLY CONFIDENTIAL OUTSIDE COUNSEL EYES ONLY] filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 07/03/2024) (2) |
| Jul 1, 2024 | 201 | [SEALED] Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, regarding discovery dispute. (Attachments: # 1 Exhibit A)(Gattuso, Dominick) Modified on 7/1/2024 (nms). (Entered: 07/01/2024) (0) |
| Jun 27, 2024 | 200 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding discovery dispute. (Attachments: # 1 Exhibits 1-13, # 2 Proposed Order, # 3 Certificate of Service)(Silver, Daniel) Modified on 6/27/2024 (nms). (Entered: 06/27/2024) (0) |
| Jun 20, 2024 | 199 | NOTICE OF SERVICE of (1) Second Supplemental Opening Expert Report of Adam J. Matzger, Ph.D. on Infringement of U.S. Patent No. 11,096,918 by Nanjing Noratech Pharmaceutical Co., Limited and Gerbera Therapeutics, Inc., and (2) Second Supplemental Expert Report of Aeri Park, Ph.D. on U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 06/20/2024) (3) |
| Jun 13, 2024 | 198 | NOTICE OF SERVICE of (1) Supplemental Opening Expert Report of Adam J. Matzger, Ph.D. on Infringement of U.S. Patent No. 11,096,918 by Defendants and (2) Supplemental Expert Report of Aeri Park, Ph.D. on U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/13/2024) (4) |
| Jun 12, 2024 | 196 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 7/9/2024, at 10:00 AM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 6/12/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(lah) (Entered: 06/12/2024) (0) |
| Jun 12, 2024 | 197 | NOTICE OF SERVICE of Supplemental Opening Expert Report of Dr. Jonath W. Steed Regarding the Invalidity of United States Patent No. 11,096,918 [HIGHLY CONFIDENTIAL OUTSIDE COUNSEL EYES ONLY] filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 06/12/2024) (2) |
| Jun 10, 2024 | 195 | STIPULATION and Proposed Order to Extend Time for discovery - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/10/2024 (nms). (Entered: 06/10/2024) (4) |
| May 31, 2024 | 194 | MEMORANDUM OPINION regarding claim construction of one term in U.S. Patent No. 11,096,918 (see Memorandum Opinion for further details). Signed by Judge Richard G. Andrews on 5/31/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 05/31/2024) (10) |
| May 29, 2024 | 192 | STIPULATION and [Proposed] Order to Extend Deadlines for Responsive and Reply Expert Reports by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 05/29/2024) (4) |
| May 29, 2024 | 193 | SO ORDERED Granting (D.I. 1372 in 20-md-2930-RGA; D.I. 192 in 22-cv-1395-RGA) Stipulation and Proposed Order to Extend Deadlines for Responsive and Reply Expert Reports. Signed by Judge Richard G. Andrews on 5/29/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 05/29/2024) (4) |
| May 24, 2024 | 191 | NOTICE OF SERVICE of (1) Supplemental Opening Expert Report of Adam J. Matzger, Ph.D. on Infringement of U.S. Patent No. 11,096,918 by MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited; and (2) Supplemental Expert Report of Aeri Park, Ph.D. on U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/24/2024) (3) |
| May 15, 2024 | 190 | REDACTED VERSION of 185 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/15/2024 (nms). (Entered: 05/15/2024) (30) |
| May 13, 2024 | 188 | NOTICE OF SERVICE of (1) Opening Expert Report of Adam J. Matzger, Ph.D. on Infringement of U.S. Patent No. 11,096,918 by Nanjing Noratech Pharmaceutical Co., Limited and Gerbera Therapeutics, Inc., and (2) Expert Report of Aeri Park, Ph.D. on U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/13/2024) (3) |
| May 13, 2024 | 189 | ORAL ORDER: The Court has considered the parties discovery dispute letters. (No. 20-2930, D.I. 1354, 1358). MSNs request to compel production of testing records is DENIED. The conference scheduled for 5/15/2024 is CANCELED. Defendant has not waived the work product privilege that protects the relevant testing data from discovery. Novartis decision to withdraw infringement allegations in an earlier case does not qualify as using privilege as a sword. In addition, the testing records appear to be shielded from discovery by the stipulated protective order. (See 20-2930, D.I. 80 50). Ordered by Judge Richard G. Andrews on 5/13/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 05/13/2024) (0) |
| May 10, 2024 | 186 | NOTICE requesting Clerk to remove Femi L. Masha of Husch Blackwell LLP as co-counsel. Reason for request: No Longer with Firm. (Gattuso, Dominick) (Entered: 05/10/2024) (2) |
| May 10, 2024 | 187 | NOTICE OF SERVICE of (1) Opening Expert Report of Dr. Jonathan W. Steed Regarding the Invalidity of United States Patent No. 11,096,918 [HIGHLY CONFIDENTIAL OUTSIDE COUNSEL EYES ONLY UNDER D. DEL. L. R. 26.2] and (2) Opening Expert Report of Dr. Hossein Ardehali Regarding the Invalidity of United States Patent No. 11,096,918 [HIGHLY CONFIDENTIAL OUTSIDE COUNSEL EYES ONLY UNDER D. DEL. L. R. 26.2] filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 05/10/2024) (2) |
| May 8, 2024 | 185 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding response to MSN's May 6, 2024 discovery dispute letter. (Attachments: # 1 Exhibits A-E, # 2 Proposed Order, # 3 Certificate of Service)(Silver, Daniel) Modified on 5/8/2024 (nms). (Entered: 05/08/2024) (0) |
| May 7, 2024 | 184 | PROPOSED Order re 183 Letter, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 5/8/2024 (nms). (Entered: 05/07/2024) (1) |
| May 6, 2024 | 183 | Letter to The Honorable Richard G. Andrews, from Richard C. Weinblatt, regarding discovery dispute. (Weinblatt, Richard) Modified on 5/7/2024 (nms). (Entered: 05/06/2024) (5) |
| Apr 30, 2024 | 182 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Gerbera Therapeutics Inc.. (Gattuso, Dominick) (Entered: 04/30/2024) (2) |
| Apr 26, 2024 | 180 | STIPULATION and [Proposed] Order Joining Gerbera Therapeutics, Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 04/26/2024) (7) |
| Apr 26, 2024 | 181 | SO ORDERED Granting (D.I. 180 in 22-cv-01395-RGA; D.I. 1339 in 20-md-02930-RGA; D.I. 68 in 23-cv-401-RGA) Stipulation and Proposed Order Joining Gerbera Therapeutics, Inc.. Signed by Judge Richard G. Andrews on 4/26/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 04/26/2024) (7) |
| Apr 16, 2024 | 179 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 5/15/2024, at 2:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 4/16/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 04/16/2024) (0) |
| Apr 15, 2024 | 178 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 4/30/2024, at 2:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 4/15/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 04/15/2024) (0) |
| Apr 12, 2024 | 177 | ORAL ORDER: The discovery conference scheduled for 4/23/2024, is now CANCELED. The parties have advised the dispute has been resolved. Ordered by Judge Richard G. Andrews on 4/12/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 04/12/2024) (0) |
| Apr 8, 2024 | 176 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendant Nanjing Noratech Pharmaceuticals Co., Limited's Second Set of Interrogatories to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 4-8) and (2) Plaintiff's Supplemental Infringement Claim Chart for U.S. Patent No. 11,096,918 Against Nanjing Noratech Pharmaceuticals Co., Limited, and (3) Plaintiff's Supplemental Infringement Claim Chart for U.S. Patent No. 11,096,918 Against MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 04/08/2024) (4) |
| Apr 5, 2024 | 174 | NOTICE OF SERVICE of Defendants' Joint Amended Invalidity Contentions for U.S. Patent No. 11,096,918 [HIGHLY CONFIDENTIAL] filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 04/05/2024) (2) |
| Apr 5, 2024 | 175 | NOTICE OF SERVICE of Nanjing Noratech Pharmaceutical Co., Limited's Amended Invalidity Contentions for U.S. Patent Nos.11,058,667 and 8,101,659 filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 04/05/2024) (2) |
| Apr 4, 2024 | 173 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited's First Supplemental Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1-3) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 04/04/2024) (2) |
| Apr 3, 2024 | 171 | NOTICE OF SERVICE of (1) MSN Defendants Second Supplemental Responses and Objections to Plaintiffs Interrogatories Nos. 4 and 5 and (2) MSN Defendants Supplemental Responses and Objections to Plaintiffs First Set of Requests for Admission (Nos. 1-8) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 04/03/2024) (2) |
| Apr 3, 2024 | 172 | Official Transcript of Markman Hearing held on 3/12/24 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/24/2024. Redacted Transcript Deadline set for 5/6/2024. Release of Transcript Restriction set for 7/2/2024. (Triozzi, Heather) (Entered: 04/03/2024) (57) |
| Apr 2, 2024 | 168 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 4/23/2024, at 2:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 4/2/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA. (lah) (Entered: 04/02/2024) (0) |
| Apr 2, 2024 | 169 | NOTICE OF SERVICE of (1) MSN Pharmaceuticals Inc., MSN Laboratories Private Limited and MSN Life Sciences Private Limiteds Responses and Objections to Novartiss Notice of Deposition Under Fed. R. Civ. P. 30(b)(6), (2) Defendants Responses and Objections to Novartiss Second Set of Interrogatories Nos. 6-7 and (3) MSN Defendants Responses and Objections to Novartiss Second Set of Requests for the Production of Documents and Things (No. 28) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 04/02/2024) (2) |
| Apr 2, 2024 | 170 | NOTICE OF SERVICE of (1) MSN Pharmaceuticals Inc., MSN Laboratories Private Limited and MSN Life Sciences Private Limiteds Responses and Objections to Novartiss Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) and (2) MSN Defendants Response and Objections to Plaintiffs Request for Admission filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 04/02/2024) (2) |
| Apr 1, 2024 | 167 | NOTICE OF SERVICE of (i) Nanjing Noratech Pharmaceutical Co., Limited's Responses and Objections to Novartis Requests for Admission to Establish the Authenticity of Documents and/or Establish Documents as Business Records; (ii) Nanjing Noratech Pharmaceutical Co., Limited's Responses and Objections to Novartis Second Set of Interrogatories (Nos. 9-10); (iii) Nanjing Noratech Pharmaceutical Co., Limited's Responses and Objections to Novartis First Set of Requests For Admissions (Nos. 1-36) [HIGHLY CONFIDENTIAL-PURSUANT TO PROTECTIVE ORDER]; (iv) Noratechs Response to Novartis' First Set of Requests to Nanjing Noratech Pharmaceutical Co., Limited for the Production of Documents and Things (Nos. 1-37); and, (v) Responses and Objections to Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Nanjing Noratech Pharmaceutical Co., Limited filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 04/01/2024) (3) |
| Mar 27, 2024 | 165 | Post-Markman Reply Supplemental Brief, filed by Nanjing Noratech Pharmaceutical Co., Limited. and MSN Defendants. (Gattuso, Dominick) Modified on 3/27/2024 (nms). (Entered: 03/27/2024) (3) |
| Mar 26, 2024 | 164 | Letter to The Honorable Richard G. Andrews, from Alexandra M. Joyce, regarding Novartis's supplemental claim construction pursuant to Courts Order at the Markman Hearing. (Attachments: # 1 Exhibit 1)(Joyce, Alexandra) Modified on 3/27/2024 (nms). (Entered: 03/26/2024) (0) |
| Mar 22, 2024 | 162 | NOTICE OF SERVICE of Novartis's Objections and Responses to Nanjing Noratech Pharmaceutical Co., Limited's Third Set of Requests for the Production of Document and Things (Nos. 24-27) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 03/22/2024) (3) |
| Mar 22, 2024 | 163 | Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso and Richard Weinblatt, regarding post Markman Hearing supplement. (Gattuso, Dominick) Modified on 3/25/2024 (nms). (Entered: 03/22/2024) (5) |
| Mar 15, 2024 | 161 | NOTICE OF SERVICE of (1) Defendants Notice of Deposition of Bin Hu, (2) Defendants Notice of Deposition of Lili Feng, (3) Defendants Notice of Deposition of Mahavir Prashad, (4) Defendants Notice of Deposition of Michael J. Girgis, (5) Defendants Notice of Deposition of Paul Allen Sutton, (6) Defendants Notice of Deposition of Piotr Karpinski, (7) Defendants Notice of Deposition of Sven Erik Godtfredsen, (8) Defendants Notice of Deposition of Thomas J. Blacklock, and (9) Defendants Notice of Deposition of Yugang Liu filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 03/15/2024) (2) |
| Mar 11, 2024 | 160 | NOTICE of Appearance by Maliheh Zare on behalf of Novartis Pharmaceuticals Corporation (Zare, Maliheh) (Entered: 03/11/2024) (1) |
| Mar 8, 2024 | 159 | ORAL ORDER: The Markman Hearing set for 3/12/2024, will now begin at 9:30 AM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 3/8/2024. (nms) (Entered: 03/08/2024) (0) |
| Mar 6, 2024 | 158 | NOTICE OF SERVICE of Nanjing Noratech Pharmaceutical Co., Limited's Second Set of Interrogatories to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 4-8) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 03/06/2024) (2) |
| Mar 5, 2024 | 157 | REDACTED VERSION of 150 Stipulation of Dismissal, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/6/2024 (nms). (Entered: 03/05/2024) (4) |
| Mar 1, 2024 | 156 | NOTICE OF SERVICE of (1) Novartis's Requests for Admission to MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited to Establish the Authenticity of Documents or Establish Documents as Business Records, and (2) Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 03/01/2024) (3) |
| Feb 29, 2024 | 152 | NOTICE OF SERVICE of (1) Novartis's Second Set of Interrogatories to MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited (Nos. 6-7); (2) Novartis's Second Set of Requests to MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited for the Production of Documents and Things; and (3) Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 02/29/2024) (3) |
| Feb 29, 2024 | 153 | NOTICE OF SERVICE of (1) Novartis's Requests for Admission to Nanjing Noratech Pharmaceutical Co., Limited to Establish the Authenticity of Documents and/or Establish Documents as Business Record and (2) Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Nanjing Noratech Pharmaceutical Co., Limited filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 02/29/2024) (3) |
| Feb 29, 2024 | 154 | Joint Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Proposed Order)(Joyce, Alexandra) Modified on 2/29/2024 (nms). (Entered: 02/29/2024) (0) |
| Feb 29, 2024 | 155 | ORDER Granting Joint Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices ( (D.I. 154 in 22-cv-1395-RGA; D.I. 1291 in 20-md-2930-RGA). Signed by Judge Richard G. Andrews on 2/29/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 02/29/2024) (2) |
| Feb 27, 2024 | 149 | SO ORDERED Granting (D.I. 148 in 22-cv-1395-RGA; D.I. 1281 in 20-md-2930-RGA) MOTION for Claim Construction Hearing. Signed by Judge Richard G. Andrews on 2/27/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 02/27/2024) (4) |
| Feb 27, 2024 | 150 | [SEALED] STIPULATION of Dismissal by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 02/27/2024) (0) |
| Feb 27, 2024 | 151 | [SEALED] ORDER Granting (D.I. 124 in 22-cv-451-RGA; D.I. 1283 in 20-md-2930-RGA; D.I. 150 in 22-cv-1395-RGA) Stipulation and Order of Dismissal between Plaintiff and Defendant Mylan Pharmaceuticals Inc.. Signed by Judge Richard G. Andrews on 2/27/2024.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-00451-RGA, 1:22-cv-01395-RGA(nms) (Entered: 02/27/2024) (0) |
| Feb 23, 2024 | 146 | JOINT Claim Construction Brief Regarding U.S. Patent No. 11,096,918, filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/23/2024 (nms). (Entered: 02/23/2024) (30) |
| Feb 23, 2024 | 147 | Joint Appendix to 146 Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibits 1-10) (Joyce, Alexandra) Modified on 2/23/2024 (nms). (Entered: 02/23/2024) (0) |
| Feb 23, 2024 | 148 | MOTION for Claim Construction Hearing - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/23/2024 (nms). (Entered: 02/23/2024) (4) |
| Feb 21, 2024 | 145 | REDACTED VERSION of 139 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/22/2024 (nms). (Entered: 02/21/2024) (6) |
| Feb 20, 2024 | 144 | NOTICE OF SERVICE of Nanjing Noratech Pharmaceutical Co., Limited's Third Set of Requests for Production of Documents and Things to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 24-27) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 02/20/2024) (2) |
| Feb 13, 2024 | 143 | STIPULATION and Proposed Order to Extend Time to file public version of the [Proposed] Consent Judgment and Order of Injunction to February 20, 2024 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 2/13/2024 (nms). (Entered: 02/13/2024) (3) |
| Feb 9, 2024 | 142 | NOTICE OF SERVICE of Defendants' Sur-Reply Claim Construction Brief filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 02/09/2024) (2) |
| Feb 7, 2024 | 140 | [SEALED] Consent Judgment and Order of Injunction between Plaintiff and Defendants Alembic Global Holding SA, Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. Signed by Judge Richard G. Andrews on 2/7/2024.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02021-RGA, 1:20-cv-00074-RGA, 1:22-cv-01395-RGA(nms) (Entered: 02/07/2024) (0) |
| Feb 6, 2024 | 139 | [SEALED] Proposed Consent Judgment and Order of Injunction, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/6/2024 (nms). (Entered: 02/06/2024) (0) |
| Jan 30, 2024 | 138 | REDACTED VERSION of 136 Sealed Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 1/31/2024 (nms). (Entered: 01/30/2024) (5) |
| Jan 23, 2024 | 136 | [SEALED] STIPULATION and [Proposed] Order Staying Mylan Actions by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 01/23/2024) (0) |
| Jan 23, 2024 | 137 | [SEALED] SO ORDERED Granting (D.I. 136 in 22-cv-1395-RGA; D.I. 1238 in 20-md-2930-RGA; D.I. 121 in 22-cv-451-RGA) Stipulation and Proposed Order Staying Mylan Actions. Signed by Judge Richard G. Andrews on 1/23/2024.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-00451-RGA, 1:22-cv-01395-RGA(nms) (Entered: 01/23/2024) (0) |
| Jan 15, 2024 | 135 | NOTICE OF SERVICE of Novartis's Reply Claim Construction Brief Regarding U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 01/15/2024) (4) |
| Dec 22, 2023 | 134 | NOTICE OF SERVICE of Novartis's Supplemental Objections and Responses to Defendant Nanjing Noratech Pharmaceutical Co., Limited's First Set of Interrogatories to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 1-3) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/22/2023) (3) |
| Dec 19, 2023 | 133 | NOTICE to Take Deposition of Dr. Edmund J. Elder, Jr. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/19/2023) (2) |
| Dec 18, 2023 | 132 | NOTICE OF SERVICE of (i) Nanjing Noratech Pharmaceutical Co., Limited's Responses and Objections to Novartis's Second Set of Interrogatories (No. 4-7); and, (ii) Nanjing Noratech Pharmaceutical Co., Limited's Response and Objections to Novartis's Second Set of Requests for the Production of Documents and Things (No. 29) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 12/18/2023) (2) |
| Dec 15, 2023 | 131 | NOTICE OF SERVICE of Defendants' Answering Claim Construction Brief (with Exhibits A-G) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 12/15/2023) (2) |
| Dec 13, 2023 | 130 | NOTICE OF SERVICE of (1) MSN Defendants Supplemental Responses and Objections to Plaintiffs Interrogatories Nos. 3, 4, and 5 and (2) MSN Defendants Supplemental Responses and Objections to Plaintiffs First Set of Requests for Admission (Nos. 1-9) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 12/13/2023) (2) |
| Dec 1, 2023 | 129 | REDACTED VERSION of 125 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 12/4/2023 (nms). (Entered: 12/01/2023) (6) |
| Nov 29, 2023 | 128 | REDACTED VERSION of 120 Letter, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibits A-J)(Gattuso, Dominick) Modified on 11/29/2023 (nms). (Entered: 11/29/2023) (0) |
| Nov 27, 2023 | 126 | STIPULATION and Order to Extend Time to file redacted version of discovery dispute letter to 12/1/2023 - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/27/2023 (nms). (Entered: 11/27/2023) (3) |
| Nov 27, 2023 | 127 | SO ORDERED Granting (D.I. 1204 in 20-md-2930-RGA; D.I. 124 in 22-cv-1395-RGA) Stipulation and Proposed Order Dismissing Mylan Laboratories Limited and Viatris, Inc. and Amending Caption. Signed by Judge Richard G. Andrews on 11/27/2023. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 11/27/2023) (4) |
| Nov 21, 2023 | 124 | STIPULATION and [Proposed] Order Dismissing Mylan Laboratories Limited and Viatris Inc. and Amending Caption by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 11/21/2023) (4) |
| Nov 21, 2023 | 125 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding response to Noratech's letter concerning discovery dispute. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 11/21/2023 (nms). (Entered: 11/21/2023) (0) |
| Nov 20, 2023 | 122 | NOTICE OF SERVICE of Novartis's Opening Claim Construction Brief Regarding U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/20/2023) (4) |
| Nov 20, 2023 | 123 | NOTICE OF SERVICE of (1) Novartis's Second Set of Interrogatories to Nanjing Noratech Pharmaceutical Co., Limited (Nos. 47) and (2) Novartis's Second Set of Requests to Nanjing Noratech Pharmaceutical Co., Limited For the Production of Documents and Things (No. 29) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/20/2023) (3) |
| Nov 17, 2023 | 120 | [SEALED] Letter to The Honorable Richard G. Andrews, from Dominick T. Gattuso, Esq., regarding discovery dispute. (Attachments: # 1 Exhibits A-J, # 2 Certificate of Service)(Gattuso, Dominick) Modified on 11/20/2023 (nms). (Entered: 11/17/2023) (0) |
| Nov 17, 2023 | 121 | PROPOSED Order for 120 Letter, by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/20/2023 (nms). (Entered: 11/17/2023) (2) |
| Nov 14, 2023 | 119 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 11/30/2023 at 2:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 11/14/2023. Associated Cases: 1:20-md-02930-RGA, 1:23-cv-401-RGA, 1:22-cv-01395-RGA (lah) Modified on 11/20/2023 (lah). (Entered: 11/14/2023) (0) |
| Nov 8, 2023 | 118 | NOTICE OF SERVICE of Novartis's Objections and Responses to Nanjing Noratech Pharmaceutical Co., Limited's Second Set of Requests for the Production of Documents and Things (Nos. 18-23) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/08/2023) (2) |
| Oct 20, 2023 | 117 | Joint Claim Construction Chart, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-10, # 2 Exhibits 11-25)(Joyce, Alexandra) Modified on 10/20/2023 (nms). (Entered: 10/20/2023) (0) |
| Oct 13, 2023 | 116 | ANSWER to 1 Complaint,, by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 10/13/2023) (21) |
| Oct 11, 2023 | 115 | NOTICE of Appearance by Denise Seastone Kraft on behalf of Nanjing Noratech Pharmaceutical Co., Limited (Kraft, Denise) (Entered: 10/11/2023) (1) |
| Oct 9, 2023 | 113 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited's Second Set of Requests for Production of Documents and Things to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 18-23) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 10/09/2023) (2) |
| Oct 9, 2023 | 114 | NOTICE OF SERVICE of Novartis's Rebuttal Proposed Construction of Claim Term and Evidence for U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 10/09/2023) (4) |
| Sep 29, 2023 | 111 | MEMORANDUM OPINION. Signed by Judge Richard G. Andrews on 9/29/2023. (lah) (Main Document 111 replaced on 10/16/2023) (nms). (Entered: 09/29/2023) (10) |
| Sep 29, 2023 | 112 | ORDER: Noratech's motion to dismiss (D.I. 26 ) and MSN's motion for judgment on the pleadings (D.I. 65 ) are DENIED. Signed by Judge Richard G. Andrews on 9/29/2023. (lah) (Main Document 112 replaced on 10/16/2023) (nms). (Entered: 09/29/2023) (1) |
| Sep 26, 2023 | 109 | NOTICE OF SERVICE of (1) MSN Defendants Responses and Objections to Plaintiffs First Set of Requests for Admission (Nos. 1-9), (2) MSN Defendants Responses and Objections to Plaintiffs First Set of Requests for the Production of Documents and Things (Nos. 1-27), and (3) MSN Defendants Responses and Objections to Plaintiffs First Set of Interrogatories (Nos. 1-5) filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 09/26/2023) (2) |
| Sep 26, 2023 | 110 | NOTICE OF SERVICE of Responses And Objections To Novartis's First Set Of Requests To Mylan Pharmaceuticals Inc., Mylan Laboratories Limited, And Viatris Inc. For The Production Of Documents And Things [Highly Confidential-Attorneys' Eyes Only]; and Responses And Objections To Novartis's First Set Of Interrogatories To Mylan Pharmaceuticals Inc., Mylan Laboratories Limited, And Viatris Inc. (Nos. 1-3) [Highly Confidential-Attorneys' Eyes Only] filed by Mylan Pharmaceuticals Inc., Mylan Laboratories Limited, Viatris Inc..(Palapura, Bindu) (Entered: 09/26/2023) (2) |
| Sep 25, 2023 | 107 | NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.'s Responses and Objections to Plaintiff Novartis Pharmaceuticals Corporation's, (1) First Set of Interrogatories (Nos. 1-4); (2) First Set of Requests for Admission (Nos. 1-5); and (3) First Set of Requests or the Production of Documents and Things (Nos. 1-27) filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Taylor, Daniel) (Entered: 09/25/2023) (2) |
| Sep 25, 2023 | 108 | NOTICE OF SERVICE of (i) Defendant Nanjing Noratech Pharmaceutical Co., Limited's Responses and Objections to Plaintiff's First Set of Requests for Production [HIGHLY CONFIDENTIAL] and; (ii) Defendant Nanjing Noratech Pharmaceutical Co., Limited's Responses and Objections to Plaintiffs First Set of Interrogatories (Nos. 1-3) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 09/25/2023) (2) |
| Sep 14, 2023 | 106 | MOTION for Pro Hac Vice Appearance of Attorney Thomas P. Heneghan of the law firm of Husch Blackwell LLP - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 09/14/2023) (4) |
| Sep 11, 2023 | 105 | NOTICE OF SERVICE of Defendants' Preliminary Claim Constructions and Supporting Evidence [HIGHLY CONFIDENTIAL] filed by Mylan Pharmaceuticals Inc., Alembic Global Holding SA, Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., Crystal Pharmaceutical (Suzhou) Co., Ltd., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Mylan Laboratories Limited, Nanjing Noratech Pharmaceutical Co., Limited, Viatris Inc..(Palapura, Bindu) (Entered: 09/11/2023) (2) |
| Sep 8, 2023 | 104 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendant Nanjing Noratech Pharmaceutical Co., Limited's First Set of Interrogatories to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 1-3) (C.A. No. 22-1395-RGA), and (2) Novartis's Responses and Objections to Defendant Nanjing Noratech Pharmaceutical Co., Limited's First Set of Interrogatories (Nos. 1-2) (C.A. No. 23-401-RGA) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/08/2023) (3) |
| Aug 29, 2023 | 103 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' First Set of Joint Requests for the Production of Documents and Things (Nos. 1-39), (2) Novartis's Objections and Responses to Noratech's First Set of Requests for the Production of Documents and Things (Nos. 1-17), and (3) Novartis's Objections and Responses to Alembic's First Set of Requests for the Production of Documents and Things (Nos. 1-7) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/29/2023) (5) |
| Aug 23, 2023 | 102 | NOTICE OF SERVICE of (1) Novartis's First Set of Interrogatories to Defendants, (2) Novartis's First Set of Requests to Defendants for the Production of Documents and Things, and (3) Novartis's First Set of Requests for Admission to Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/23/2023) (5) |
| Aug 17, 2023 | 101 | NOTICE OF SERVICE of (1) Objections and Responses to MSN's First Interrogatory, and (2) Objections and Responses to MSN's First Set of Joint Requests for the Production of Documents and Things (Nos. 1-4) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/17/2023) (2) |
| Aug 8, 2023 | 100 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited's First Set of Interrogatories to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 1-3) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 08/08/2023) (2) |
| Aug 4, 2023 | 98 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited's Initial Invalidity Contentions for U.S. Patent Nos.11,058,667 and 8,101,659 filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 08/04/2023) (2) |
| Aug 4, 2023 | 99 | NOTICE OF SERVICE of Defendants Joint Initial Invalidity Contentions filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 08/04/2023) (2) |
| Jul 28, 2023 | 97 | NOTICE OF SERVICE of Defendants' First Set of Joint Requests for the Production of Documents and Things (Nos. 1-39) to Plaintiff Novartis Pharmaceuticals Corporation filed by Mylan Pharmaceuticals Inc., Mylan Laboratories Limited.(Palapura, Bindu) (Entered: 07/28/2023) (2) |
| Jul 27, 2023 | 95 | NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.'s First Set of Requests for the Production of Documents and Things (Nos. 1-7) filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Taylor, Daniel) (Entered: 07/27/2023) (2) |
| Jul 27, 2023 | 96 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limiteds First Set of Requests for Production of Documents and Things to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 1-17) filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 07/27/2023) (2) |
| Jul 24, 2023 | 94 | NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.'s updated ANDA documents and FDA correspondence filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Taylor, Daniel) (Entered: 07/24/2023) (2) |
| Jul 17, 2023 | 92 | NOTICE OF SERVICE of Defendants Mylan Pharmaceuticals Inc.'s, Mylan Laboratories Limited's And Viatris Inc.'s Initial Disclosures Pursuant To Rule 26(A)(1) And Paragraph 3 Of The Delaware Default Standard For Discovery filed by Mylan Pharmaceuticals Inc., Mylan Laboratories Limited.(Palapura, Bindu) (Entered: 07/17/2023) (2) |
| Jul 17, 2023 | 93 | NOTICE OF SERVICE of (1) Defendants MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limiteds First Set of Requests for Documents and Things (Nos. 1-4) to Plaintiff Novartis Pharmaceuticals Corporation and (2) Defendants MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limiteds First Interrogatory to Novartis Pharmaceuticals Corporation filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 07/17/2023) (2) |
| Jul 14, 2023 | 90 | NOTICE OF SERVICE of (1) Novartis's Rule 26(a) Initial Disclosures regarding the '659 and '667 Patents, (2) Novartis's Initial Paragraph 3 Disclosures Regarding Electronic Systems Information regarding the '659 and '667 Patents, and (3) Novartis's Initial Infringement Charts Against Defendants regarding the '659 and '667 Patents filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 07/14/2023) (5) |
| Jul 14, 2023 | 91 | MOTION for Pro Hac Vice Appearance of Attorney Matthew M. Kamps of Husch Blackwell LLP - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 07/14/2023) (4) |
| Jul 13, 2023 | 87 | NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.'s Initial Disclosures, Including Discovery of Electronically Stored Information ("ESI") (the "Default Standard") filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc..(Taylor, Daniel) (Entered: 07/13/2023) (2) |
| Jul 13, 2023 | 88 | NOTICE OF SERVICE of (1) MSN Laboratories Private Limiteds and MSN Pharmaceuticals Inc.s Initial Rule 26(a)(1) Disclosures and (2) MSN Laboratories Private Limiteds and MSN Pharmaceuticals Inc.s Initial ESI Disclosures filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 07/13/2023) (2) |
| Jul 13, 2023 | 89 | NOTICE OF SERVICE of Defendant Nanjing Noratech Pharmaceutical Co., Limited's Fed. R. Civ. P. Rule 26(a)(1)(A) and Paragraph 3 Disclosures filed by Nanjing Noratech Pharmaceutical Co., Limited.(Gattuso, Dominick) (Entered: 07/13/2023) (2) |
| Jul 7, 2023 | 86 | REDACTED VERSION of 82 Stipulation and Proposed Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/7/2023 (nms). (Entered: 07/07/2023) (6) |
| Jul 6, 2023 | 85 | SCHEDULING ORDER: Joinder of Parties due by 11/3/2023. Amended Pleadings due by 11/3/2023. Fact Discovery completed by 4/5/2024. Joint Claim Construction Brief due by 2/23/2024. A Markman Hearing is set for 3/12/2024, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 11/22/2024, at 9:00 AM in Courtroom 6A. A Bench Trial is set to start 12/9/2024, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 7/6/2023. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 07/06/2023) (18) |
| Jul 5, 2023 | 84 | PROPOSED Scheduling Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/6/2023 (nms). (Entered: 07/05/2023) (18) |
| Jun 30, 2023 | 82 | [SEALED] STIPULATION and [Proposed] Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/30/2023 (nms). (Entered: 06/30/2023) (0) |
| Jun 30, 2023 | 83 | [SEALED] ORDER Granting (16 in 23-cv-401-RGA; 82 in 22-cv-1395-RGA; 176 in 21-cv-1330-RGA; 1091 in 20-md-2930-RGA; 95 in 22-cv-451-RGA) Stipulation and Proposed Order. Signed by Judge Richard G. Andrews on 6/30/2023.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:22-cv-00451-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 06/30/2023) (0) |
| Jun 29, 2023 | 81 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Main Document) (4) |
| Jun 29, 2023 | 81 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Certification for Melinda R. Roberts) (1) |
| Jun 21, 2023 | 80 | REDACTED VERSION of 79 Reply Brief, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibits D-F)(Weinblatt, Richard) Modified on 6/22/2023 (nms). (Entered: 06/21/2023) (Main Document) (11) |
| Jun 21, 2023 | 80 | REDACTED VERSION of 79 Reply Brief, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibits D-F)(Weinblatt, Richard) Modified on 6/22/2023 (nms). (Entered: 06/21/2023) (Exhibit D-F) (30) |
| Jun 6, 2023 | 77 | REDACTED VERSION of 70 Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 6/6/2023 (nms). (Entered: 06/06/2023) (18) |
| Jun 6, 2023 | 78 | REDACTED VERSION of 71 Declaration, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 6/6/2023 (nms). (Entered: 06/06/2023) (25) |
| Jun 6, 2023 | 79 | [SEALED] REPLY BRIEF re 65 MOTION for Judgment on the Pleadings filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibits D-F)(Weinblatt, Richard) (Entered: 06/06/2023) (0) |
| Jun 5, 2023 | 76 | REDACTED VERSION of 66 Opening Brief in Support, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A-C)(Stamoulis, Stamatios) (Entered: 06/05/2023) (Main Document) (16) |
| Jun 5, 2023 | 76 | REDACTED VERSION of 66 Opening Brief in Support, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A-C)(Stamoulis, Stamatios) (Entered: 06/05/2023) (Exhibit A-C) (30) |
| Jun 2, 2023 | 74 | REDACTED VERSION of 67 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/2/2023 (nms). (Entered: 06/02/2023) (6) |
| Jun 2, 2023 | 75 | REDACTED VERSION of 68 Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 06/02/2023) (6) |
| Jun 1, 2023 | 72 | ORAL ORDER: Due to a scheduling conflict the Rule 16(b) Conference set for 6/1/2023, will now commence at 4:00 PM in Courtroom 6A. Signed by Judge Richard G. Andrews on 6/1/2023. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 06/01/2023) (0) |
| Jun 1, 2023 | 73 | Amended Proposed Scheduling Order, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 6/1/2023 (nms). (Entered: 06/01/2023) (19) |
| May 30, 2023 | 68 | [SEALED] CONSENT JUDGMENT and Order of Injunction between Crystal Pharmaceutical (Suzhou) Co., Ltd. and Novartis Pharmaceuticals Corporation. Signed by Judge Richard G. Andrews on 5/30/2023.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:21-cv-01452-RGA, 1:22-cv-01395-RGA(nms) (Entered: 05/30/2023) (0) |
| May 30, 2023 | 69 | PROPOSED Scheduling Order, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 5/30/2023 (nms). (Entered: 05/30/2023) (20) |
| May 30, 2023 | 70 | [SEALED] ANSWERING BRIEF in Opposition re 65 MOTION for Judgment on the Pleadings filed by Novartis Pharmaceuticals Corporation.Reply Brief due date per Local Rules is 6/6/2023. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 05/30/2023) (0) |
| May 30, 2023 | 71 | [SEALED] DECLARATION of Christopher Loh re 70 Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-F, # 2 Certificate of Service)(Silver, Daniel) Modified on 5/31/2023 (nms). (Entered: 05/30/2023) (0) |
| May 26, 2023 | 67 | [SEALED] Proposed Consent Judgment and Order of Injunction between Plaintiff and Crystal Defendant, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/26/2023 (nms). (Entered: 05/26/2023) (0) |
| May 22, 2023 | 65 | MOTION for Judgment on the Pleadings - filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) (Entered: 05/22/2023) (2) |
| May 22, 2023 | 66 | [SEALED] OPENING BRIEF in Support re 65 MOTION for Judgment on the Pleadings filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..Answering Brief/Response due date per Local Rules is 6/5/2023. (Attachments: # 1 Exhibits A-C)(Weinblatt, Richard) (Entered: 05/22/2023) (0) |
| May 18, 2023 | 64 | MOTION for Pro Hac Vice Appearance of Attorney Melanie Black Dubis of Parker Poe Adams & Bernstein LLP - filed by Mylan Pharmaceuticals Inc., Mylan Laboratories Limited, Viatris Inc.. (Moore, David) (Entered: 05/18/2023) (3) |
| Apr 13, 2023 | 62 | Order Setting Rule 16(b) Conference: A Scheduling Conference is set for 6/1/2023, at 3:30 PM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 4/13/2023. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 04/13/2023) (1) |
| Apr 13, 2023 | 63 | NOTICE of Appearance by Daniel Taylor on behalf of Alembic Global Holding SA, Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc. (Taylor, Daniel) (Entered: 04/13/2023) (1) |
| Apr 11, 2023 | 61 | SO ORDERED Granting (D.I. 983 in 20-md-2930-RGA; D.I. 60 in 22-cv-1395-RGA) Stipulation and Proposed Order to Bifurcate and Stay Certain Defenses and Counterclaims. Signed by Judge Richard G. Andrews on 4/11/2023. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA(nms) (Entered: 04/11/2023) (5) |
| Apr 10, 2023 | 60 | STIPULATION and [Proposed] Order to Bifurcate and Stay Certain Defenses and Counterclaims by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 04/10/2023) (5) |
| Mar 22, 2023 | 59 | NOTICE of Change of Address by Alexandra M. Joyce (Joyce, Alexandra) (Entered: 03/22/2023) (5) |
| Mar 20, 2023 | 57 | ANSWER to 1 Complaint with Additional Defenses, by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., amd Alembic Global Holding SA.(Belgam, Neal) Modified on 3/20/2023 (nms). Modified on 3/21/2023 (nms). (Entered: 03/20/2023) (30) |
| Mar 20, 2023 | 58 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed, filed by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc., and Alembic Global Holding SA. (Belgam, Neal) Modified on 3/21/2023 (nms). (Entered: 03/20/2023) (2) |
| Mar 17, 2023 | 56 | NOTICE of Withdrawal of Appearance of Delaware Counsel, Eve Ormerod by Alembic Global Holding SA, Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc. (Ormerod, Eve) (Entered: 03/17/2023) (1) |
| Mar 15, 2023 | 55 | ANSWER to 47 Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 03/15/2023) (30) |
| Feb 7, 2023 | 54 | ANSWER to 49 Answer to Complaint, and Counterclaims, by Novartis Pharmaceuticals Corporation.(Silver, Daniel) Modified on 2/8/2023 (nms). (Entered: 02/07/2023) (7) |
| Feb 6, 2023 | 53 | STIPULATION and Order to Extend Time - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/6/2023 (nms). (Entered: 02/06/2023) (3) |
| Jan 18, 2023 | 50 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Mylan Inc. for Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.; Corporate Parent none for Viatris Inc. filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Palapura, Bindu) (Entered: 01/18/2023) (2) |
| Jan 18, 2023 | 51 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 01/18/2023) (2) |
| Jan 18, 2023 | 52 | MOTION for Pro Hac Vice Appearance of Attorney Robert L. Florence and Tasneem A. Dharamsi of Parker Poe Adams & Bernstein LLP - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Moore, David) (Entered: 01/18/2023) (4) |
| Jan 17, 2023 | 47 | ANSWER to 1 Complaint, with Jury Demand and COUNTERCLAIMS against All Plaintiffs, by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) Modified on 1/18/2023 (nms). (Entered: 01/17/2023) (30) |
| Jan 17, 2023 | 48 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Crystal Pharmatech Co., Ltd. for Crystal Pharmaceutical (Suzhou) Co., Ltd. filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) (Entered: 01/17/2023) (2) |
| Jan 17, 2023 | 49 | ANSWER to 1 Complaint, Affirmative Defenses and COUNTERCLAIMS against Novartis Pharmaceuticals Corporation, by Mylan Pharmaceuticals Inc., Viatris Inc., Mylan Laboratories Limited.(Palapura, Bindu) Modified on 1/18/2023 (nms). (Entered: 01/17/2023) (30) |
| Jan 13, 2023 | 46 | STIPULATION and Order to Extend Time for Crystal to answer, move or otherwise respond to the Complaint to January 17, 2023 - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) Modified on 1/13/2023 (nms). (Entered: 01/13/2023) (3) |
| Jan 6, 2023 | 42 | STIPULATION and Proposed Order to Extend Time to answer, move, or otherwise respond to the Complaint to March 20, 2023 - filed by Alembic Global Holding SA, Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. (Ormerod, Eve) Modified on 1/6/2023 (nms). (Entered: 01/06/2023) (2) |
| Jan 6, 2023 | 43 | ANSWER to 33 Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 01/06/2023) (13) |
| Jan 6, 2023 | 44 | REPLY BRIEF re 26 MOTION to Dismiss for Failure to State a Claim filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 01/06/2023) (14) |
| Jan 6, 2023 | 45 | REQUEST for Oral Argument by Nanjing Noratech Pharmaceutical Co., Limited re 26 MOTION to Dismiss for Failure to State a Claim . (Gattuso, Dominick) (Entered: 01/06/2023) (2) |
| Dec 29, 2022 | 40 | REDACTED VERSION of 37 Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/29/2022 (nms). (Entered: 12/29/2022) (20) |
| Dec 29, 2022 | 41 | REDACTED VERSION of 38 Declaration of Christopher E. Loh, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/29/2022 (nms). (Entered: 12/29/2022) (9) |
| Dec 27, 2022 | 39 | STIPULATION and Order to Extend Time - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 12/27/2022 (nms). (Entered: 12/27/2022) (3) |
| Dec 22, 2022 | 37 | [SEALED] ANSWERING BRIEF in Opposition re 26 MOTION to Dismiss for Failure to State a Claim filed by Novartis Pharmaceuticals Corporation.Reply Brief due date per Local Rules is 12/29/2022. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 12/22/2022) (0) |
| Dec 22, 2022 | 38 | [SEALED] DECLARATION of Christopher E. Loh re 37 Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 12/22/2022 (nms). (Entered: 12/22/2022) (0) |
| Dec 19, 2022 | 36 | MOTION for Pro Hac Vice Appearance of Attorney Ronald M. Daignault and Richard Juang - filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) (Entered: 12/19/2022) (6) |
| Dec 16, 2022 | 33 | ANSWER to 1 Complaint, and COUNTERCLAIMS against Novartis Pharmaceuticals Corporation, by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Life Sciences Private Limited.(Weinblatt, Richard) Modified on 12/19/2022 (nms). (Entered: 12/16/2022) (30) |
| Dec 16, 2022 | 34 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent MSN Laboratories Pvt. Ltd. for MSN Life Sciences Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., MSN Pharmaceuticals Inc. filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) (Entered: 12/16/2022) (2) |
| Dec 16, 2022 | 35 | STIPULATION and Order to Extend Time to Respond to Complaint - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Palapura, Bindu) Modified on 12/19/2022 (nms). Modified on 12/19/2022 (nms). (Entered: 12/16/2022) (2) |
| Dec 14, 2022 | 32 | STIPULATION and Order to Extend Time - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) Modified on 12/14/2022 (nms). (Entered: 12/14/2022) (3) |
| Dec 6, 2022 | 31 | REDACTED VERSION of 27 Opening Brief in Support, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Certificate of Service)(Gattuso, Dominick) (Entered: 12/06/2022) (Main Document) (16) |
| Dec 6, 2022 | 31 | REDACTED VERSION of 27 Opening Brief in Support, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Certificate of Service)(Gattuso, Dominick) (Entered: 12/06/2022) (Exhibit A) (6) |
| Dec 6, 2022 | 31 | REDACTED VERSION of 27 Opening Brief in Support, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Certificate of Service)(Gattuso, Dominick) (Entered: 12/06/2022) (Exhibit B) (4) |
| Dec 6, 2022 | 31 | REDACTED VERSION of 27 Opening Brief in Support, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Certificate of Service)(Gattuso, Dominick) (Entered: 12/06/2022) (Exhibit C) (27) |
| Dec 6, 2022 | 31 | REDACTED VERSION of 27 Opening Brief in Support, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Certificate of Service)(Gattuso, Dominick) (Entered: 12/06/2022) (Exhibit D) (10) |
| Dec 6, 2022 | 31 | REDACTED VERSION of 27 Opening Brief in Support, by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Certificate of Service)(Gattuso, Dominick) (Entered: 12/06/2022) (Certificate of Service) (1) |
| Nov 28, 2022 | 30 | STIPULATION and Proposed Order to Extend Time - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/28/2022 (nms). (Entered: 11/28/2022) (2) |
| Nov 23, 2022 | 28 | ORDER Granting Motion for Leave to File Under Seal (D.I. 25 ). Signed by Judge Richard G. Andrews on 11/23/2022. (nms) (Entered: 11/23/2022) (2) |
| Nov 23, 2022 | 29 | STIPULATION and Proposed Order to Extend Time - filed by Alembic Global Holding SA, Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals, Inc.. (Ormerod, Eve) Modified on 11/23/2022 (nms). (Entered: 11/23/2022) (2) |
| Nov 22, 2022 | 25 | MOTION for Leave to File Under Seal - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Proposed Order, # 2 Exhibit 1)(Gattuso, Dominick) Modified on 11/22/2022 (nms). (Entered: 11/22/2022) (Main Document) (4) |
| Nov 22, 2022 | 26 | MOTION to Dismiss for Failure to State a Claim - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Text of Proposed Order)(Gattuso, Dominick) (Entered: 11/22/2022) (Main Document) (2) |
| Nov 22, 2022 | 27 | [SEALED] OPENING BRIEF in Support re 26 MOTION to Dismiss for Failure to State a Claim filed by Nanjing Noratech Pharmaceutical Co., Limited.Answering Brief/Response due date per Local Rules is 12/6/2022. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Certificate of Service)(Gattuso, Dominick) (Entered: 11/22/2022) (0) |
| Nov 22, 2022 | 25 | MOTION for Leave to File Under Seal - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Proposed Order, # 2 Exhibit 1)(Gattuso, Dominick) Modified on 11/22/2022 (nms). (Entered: 11/22/2022) (Text of Proposed Order) (2) |
| Nov 22, 2022 | 25 | MOTION for Leave to File Under Seal - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Proposed Order, # 2 Exhibit 1)(Gattuso, Dominick) Modified on 11/22/2022 (nms). (Entered: 11/22/2022) (Exhibit 1) (3) |
| Nov 22, 2022 | 26 | MOTION to Dismiss for Failure to State a Claim - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # 1 Text of Proposed Order)(Gattuso, Dominick) (Entered: 11/22/2022) (Text of Proposed Order) (2) |
| Nov 21, 2022 | 23 | DECLARATION of Service of MSN Laboratories Private Limited, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/21/2022 (nms). (Entered: 11/21/2022) (2) |
| Nov 21, 2022 | 24 | DECLARATION of Service of MSN Life Sciences Private Limited, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/21/2022 (nms). (Entered: 11/21/2022) (2) |
| Nov 18, 2022 | 21 | MOTION for Pro Hac Vice Appearance of Attorney Don J. Mizerk and Matthew M. Kamps, each of the law firm of Husch Blackwell LLP - filed by Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) (Entered: 11/18/2022) (5) |
| Nov 18, 2022 | 22 | MOTION for Pro Hac Vice Appearance of Attorney Scott A. Cunning II, C. Kyle Musgrove, and Elizabeth M. Crompton, each of the law firm of Parker Poe Adams & Bernstein, LLP - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) (Entered: 11/18/2022) (6) |
| Nov 16, 2022 | 12 | DECLARATION of Service of Alembic Global Holding SA, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (Main Document) (2) |
| Nov 16, 2022 | 13 | DECLARATION of Service of Alembic Pharmaceuticals Limited, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (Main Document) (2) |
| Nov 16, 2022 | 14 | DECLARATION of Service of Crystal Pharmaceuticals (Suzhou) Co., Ltd., by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (Main Document) (2) |
| Nov 16, 2022 | 15 | DECLARATION of Service of Mylan Laboratories Limited, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (2) |
| Nov 16, 2022 | 16 | DECLARATION of Service of Mylan Pharmaceuticals Inc., by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (2) |
| Nov 16, 2022 | 17 | DECLARATION of Service of Nanjing Noratech Pharmaceutical Co., Limited, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (Main Document) (2) |
| Nov 16, 2022 | 18 | STIPULATION TO EXTEND TIME for Crystal to Answer the Complaint to December 16, 2022 - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) (Entered: 11/16/2022) (3) |
| Nov 16, 2022 | 19 | STIPULATION and Order to Extend Time - filed by Nanjing Noratech Pharmaceutical Co.. (Gattuso, Dominick) Modified on 11/17/2022 (nms). Modified on 11/17/2022 (nms). (Entered: 11/16/2022) (3) |
| Nov 16, 2022 | 20 | STIPULATION and Order to Extend Time to Respond to Complaint, filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 11/17/2022 (nms). (Entered: 11/16/2022) (2) |
| Nov 16, 2022 | 14 | DECLARATION of Service of Crystal Pharmaceuticals (Suzhou) Co., Ltd., by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (Exhibit A-B) (7) |
| Nov 16, 2022 | 17 | DECLARATION of Service of Nanjing Noratech Pharmaceutical Co., Limited, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (Exhibit A-B) (7) |
| Nov 16, 2022 | 12 | DECLARATION of Service of Alembic Global Holding SA, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (Exhibit A-B) (7) |
| Nov 16, 2022 | 13 | DECLARATION of Service of Alembic Pharmaceuticals Limited, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-B)(Joyce, Alexandra) Modified on 11/16/2022 (nms). (Entered: 11/16/2022) (Exhibit A-B) (7) |
| Nov 11, 2022 | 11 | STIPULATION and Order to Extend Time to Respond to Complaint - filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Moore, David) Modified on 11/14/2022 (nms). (Entered: 11/11/2022) (2) |
| Oct 31, 2022 | 10 | MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham)(Silver, Daniel) (Entered: 10/31/2022) (Main Document) (2) |
| Oct 31, 2022 | 10 | MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham)(Silver, Daniel) (Entered: 10/31/2022) (Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, a) (4) |
| Oct 28, 2022 | 6 | SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation.Alembic Pharmaceuticals, Inc. served on 10/27/2022, answer due 11/17/2022. (Joyce, Alexandra) (Entered: 10/28/2022) (2) |
| Oct 28, 2022 | 7 | SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation.MSN Pharmaceuticals Inc. served on 10/27/2022, answer due 11/17/2022. (Joyce, Alexandra) (Entered: 10/28/2022) (2) |
| Oct 28, 2022 | 8 | SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation.Mylan Laboratories Limited served on 10/27/2022, answer due 11/17/2022. (Joyce, Alexandra) (Entered: 10/28/2022) (2) |
| Oct 28, 2022 | 9 | SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation.Viatris Inc. served on 10/27/2022, answer due 11/17/2022. (Joyce, Alexandra) (Entered: 10/28/2022) (2) |
| Oct 24, 2022 | 1 | Complaint* (1) |
| Oct 24, 2022 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (smg) (Entered: 10/25/2022) (3) |
| Oct 24, 2022 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: N/A. Date of Expiration of Patent: 11/08/2026. Stay Deadline: 7/7/2023. (smg) (Entered: 10/25/2022) (3) |
| Oct 24, 2022 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,096,918. (smg) (Entered: 10/25/2022) (1) |
| Oct 24, 2022 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (smg) (Entered: 10/25/2022) (2) |
